TP53 and colorectal carcinoma: The initial step entailed a comparative analysis of key mutations (APC, TP53, KRAS, BRAF, NRAS, and ERBB2) between the clinical cohort (n = 7936 cases), which is the collection of the public database cases, and the PDX model-derived cohort (n = 137) which is the collection of our HROC—short for Hansestadt Rostock CRC—models.